p38 Inhibitor SB203580 Inhibits HEV Infection and Prevents HEV ‐Related Adverse Pregnancy Outcomes in a Pregnant Rabbit Model
Liver International · 2026
DOI: 10.1111/liv.70811 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2026. Verfasst von Manyu Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division I of In Vitro Diagnostics for Infectious Diseases, Institute for In Vitro Diagnostics Control, State Key Laboratory of Drug Regulatory Scien…. Hauptthemen laut MEDLINE: Pyridines, Imidazoles, p38 Mitogen-Activated Protein Kinases, Hepatitis E. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background and Aims Hepatitis E virus (HEV) infection during pregnancy can lead to severe adverse pregnancy outcomes including stillbirth, preterm birth, abortion, maternal death, and vertical transmission. Off‐label use of ribavirin or pegylated interferon‐α is proved effective for treating HEV infection, but they are both contraindicated for pregnant women. A safe and effective treatment against HEV infection during pregnancy is urgently needed.
Methods
We used JEG‐3 choriocarcinoma cells to investigate the p38‐MAPK signalling pathway in HEV replication. The cells were treated with varying concentrations of SB203580, a selective p38‐MAPK inhibitor. For in vivo validation, HEV‐infected pregnant rabbits were treated with SB203580. HEV replication, cytokine secretion, apoptosis, and pathological changes were measured. The effects on pregnancy outcomes, including vertical transmission, were also monitored.
Results
In this study, with a HEV‐infected choriocarcinoma cell line, the JEG‐3 cell model, we found that HEV infection significantly altered the expression patterns of the p38‐MAPK signalling pathway. SB203580 can inhibit HEV replication and reduce the secretion of proinflammatory cytokines and apoptosis in vitro. Further in vivo validation with the HEV‐infected pregnant rabbit model also revealed that SB203580 treatment during pregnancy significantly reduced the viral load in faeces and serum, the secretion of proinflammatory cytokines, and apoptosis in placental tissues. Most importantly, SB203580 is not only safe but can also effectively prevent HEV‐related adverse pregnancy outcomes in pregnant rabbits and vertical transmission of HEV to pups.
Conclusions
These results demonstrate that the p38 inhibitor SB203580 is an effective compound with potential as a therapeutic candidate against HEV infection during pregnancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division I of In Vitro Diagnostics for Infectious Diseases, Institute for In Vitro Diagnostics Control, State Key Laboratory of Drug Regulatory Science, National Institutes for Food and Drug Control, Beijing, China.
- Institute of Human Virology, Department of Pathogen Biology and Biosecurity, Key Laboratory of Tropical Disease Control of Ministry of Education, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China.
ORCID-Profile: Manyu Li, Pengfei Wang, Qiyu He
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, M., Wan, W., Song, Z., Wang, P., Sun, W., He, Q., & Zhou, H. (2026). p38 Inhibitor SB203580 Inhibits HEV Infection and Prevents HEV ‐Related Adverse Pregnancy Outcomes in a Pregnant Rabbit Model. Liver International. https://doi.org/10.1111/liv.70811
Vancouver
Li M, Wan W, Song Z, Wang P, Sun W, He Q, et al. p38 Inhibitor SB203580 Inhibits HEV Infection and Prevents HEV ‐Related Adverse Pregnancy Outcomes in a Pregnant Rabbit Model. Liver International. 2026. doi:10.1111/liv.70811
BibTeX
@article{Li2026,
author = {Li, Manyu and Wan, Wenjun and Song, Zeyu and Wang, Pengfei and Sun, Wenwen and He, Qiyu and Zhou, Haiwei},
title = {p38 Inhibitor SB203580 Inhibits HEV Infection and Prevents HEV ‐Related Adverse Pregnancy Outcomes in a Pregnant Rabbit Model},
journal = {Liver International},
year = {2026},
doi = {10.1111/liv.70811}
}
EUVIMED